Pfizer Given Average Rating of “Buy” by Analysts (NYSE:PFE)
Shares of Pfizer (NYSE:PFE) have received a consensus rating of “Buy” from the seventeen ratings firms that are covering the company, Stock Ratings Network reports. Six analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $33.97.
A number of research firms have recently commented on PFE. Analysts at Jefferies Group reiterated a “buy” rating on shares of Pfizer in a research note on Monday, July 14th. They now have a $38.00 price target on the stock, up previously from $36.00. Separately, analysts at Barclays raised their price target on shares of Pfizer from $32.00 to $34.00 in a research note on Wednesday, July 2nd. They now have an “equal weight” rating on the stock. Finally, analysts at JPMorgan Chase & Co. initiated coverage on shares of Pfizer in a research note on Wednesday, May 28th. They set an “overweight” rating and a $35.00 price target on the stock.
Pfizer (NYSE:PFE) opened at 30.35 on Friday. Pfizer has a 1-year low of $27.76 and a 1-year high of $32.96. The stock has a 50-day moving average of $29.88 and a 200-day moving average of $30.68. The company has a market cap of $193.6 billion and a price-to-earnings ratio of 9.54. Pfizer also was the recipient of a large increase in short interest in June. As of June 30th, there was short interest totalling 65,672,029 shares, an increase of 15.8% from the June 13th total of 56,730,101 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average trading volume of 24,093,960 shares, the short-interest ratio is currently 2.7 days.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.57 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.56 by $0.01. The company had revenue of $11.35 million for the quarter, compared to the consensus estimate of $12.07 billion. During the same quarter in the prior year, the company posted $0.54 earnings per share. The company’s quarterly revenue was down 8.5% on a year-over-year basis. On average, analysts predict that Pfizer will post $2.24 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Wednesday, September 3rd. Investors of record on Friday, August 1st will be paid a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a dividend yield of 3.43%. The ex-dividend date is Wednesday, July 30th.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.